Eye Care Insider: Recent Episodes

Joshua Mali, MD

In this podcast, Joshua Mali, MD, brings you the best insights and perspectives in the field of eye care today. Through interviews with thought leaders in ophthalmology, Mali gets the inside of every story.

View Details

In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics.

Brought to you by Alcon

· Welcome to another exciting episode of Eye Care insider :14

· Intro David Eveleth, PhD :47

· Eveleth’s background 1:05

· What’s the treatment landscape now for corneal diseases and where are we falling short for patients? 2:59

· The origins of Trefoil Therapeutics 7:27

· FGF-1: Is it just important in the endothelium or is it also important in the epithelium? 11:47

· What is your current lead investigational candidate? 14:01

· When do you expect another read out of clinical data? 21:47

· An adjunctive therapy with cataract surgery 18:27

· What is the timeline of administration to patients? 19:24

· When do you expect a readout of clinical data? 20:49

· Is it possible to use this also for the epithelium? 21:39

· What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? 24:07

· For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit www.trefoiltherapeutics.com 25:53

· Corneal disease can be fixed and better vision is possible 26:44

· Thanks for listening 27:04

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera.

David Eveleth, PhD, is the president and CEO of Trefoil Therapeutics.

Disclosures: Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

View Details

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.

Brought to you by Alcon

· Welcome to another exciting episode of Eye Care insider :13

· Intro Nancy Lurker :22

· Lurker’s background :58

· EyePoint Pharmaceuticals: the origin and transition 2:29

· Yutiq and long-acting drug delivery systems 6:07

· Additional indications for Yutiq 8:30

· What is the key factor in delivering this longer durability? 16:13

· Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47

· Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19

· Investor information and neural protection data 29:01

· What is the most important issue that the field of ophthalmology is currently facing? 30:38

· Thanks for listening 32:37

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma.

Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals.

Disclosures: Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

View Details

In this episode, I discuss Samsara Vision’s SING IMT and its benefits of vision improvement for patients with AMD with Rebecca Kammer, OD, PhD.

Brought to you by Alcon

· Welcome to another exciting episode of Eye Care insider :14

· Intro for Rebecca Kammer, OD, PhD :27

· Dr. Kammer’s background 1:28

· Defining late-stage AMD patients and treatments available 5:11

· The SING IMT 9:46

· US Concerto Study Website – to learn more about the study 13:13

· Visual acuity and the SING IMT 13:48

· US trial, recruitment and patient eligibility 17:18

· Contact toll-free 1-866-393-3767 discuss eligibility, participation and questions 20:39

· SING IMT as an option for patients 22:55

· Thanks for listening 27:30

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can reach Dr. Kammer at rkammer@samsaravision.com.

Rebecca Kammer, OD, PhD, is the vice president of worldwide clinical and medical affairs for Samsara Vision, Inc., an adjunct professor at University of California, Irvine and a diplomate in low vision of the American Academy of Optometry.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI. Kammer reports being a clinical advisor to Biovisics and Eyedaptic.

View Details

In this episode, I share my top five predictions for 2023 in the field of ophthalmology.

Brought to you by Alcon

  • Welcome to another exciting episode of Eye Care insider :52
  • My review of the top five predictions in ophthalmology 1:03
  • Prediction #1 – Vabysmo and anti-VEGF market 1:53
  • Prediction #2 – FDA approval for GA treatment 4:26
  • Prediction #3 – SNAPS eye shield for ocular protection 6:06
  • Prediction #4 – biosimilars and the ophthalmic therapeutic marketplace 10:08
  • Prediction #5 – retina analytical tools 12:27
  • Thanks for listening 14:30

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

View Details

In this episode, I share my thoughts about the five greatest innovations of the 21st century in the field of ophthalmology and how they have changed patient outcomes for the better.

Brought to you by Alcon

  • Welcome to another exciting episode of Eye Care insider :50
  • My review of the top five innovations in ophthalmology 1:02
  • Greatest Innovation #1 – anti-VEGF medications 2:06
  • Greatest Innovation #2 – intraocular lens implantation technology 3:26
  • Greatest Innovation #3 – electronic medical records 4:08
  • Greatest Innovation #4 – optical coherence tomography 5:48
  • Greatest Innovation #5 – telemedicine 6:35
  • Thanks for listening 7:44

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

View Details

In this episode, I share my review of the hot topics from the AAO 2022 annual meeting and share my thoughts on the new data shared about drug trials and treatments.

Brought to you by Alcon

  • Welcome to another exciting episode of Eye Care insider :53
  • My review of the hot topics from the AAO 2022 annual meeting 2:20
  • Hot Topic #1 – wet AMD treatments 2:40
  • Hot Topic #2 – high-dose Eylea 6:20
  • Hot Topic #3 – geographic atrophy treatments 10:24
  • Thanks for listening 16:04

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

View Details

In this episode, I share my preview of the hot topics for the upcoming AAO 2022 annual meeting, including my thoughts on ocular gene therapy and new treatments in the works.

  • Welcome to another exciting episode of Eye Care insider :52
  • My preview of hot topics for the upcoming AAO 2022 annual meeting 1:04
  • Hot Topic #1 – new treatments for dry AMD or geographic atrophy 2:43
  • Hot Topic #2 – wet AMD management 5:55
  • Hot Topic #3 – ocular gene therapy 7:56
  • Hot Topic #4 – biosimilars 9:17
  • Thanks for listening 11:22

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

View Details

In this episode, Jose O. Segura, wealth management advisor and certified business exit planner, discusses establishing objectives within financial planning and organization, how to diversify your portfolio in ever-changing markets and more.

  • Intro :38
  • Welcome to another episode of Eye Care insider :52
  • About Jose Segura 1:03
  • For people that are listening for the first time, do you mind giving a brief of your background? 1:32
  • What are, in your opinion, some best practices in regard to financial planning? 2:58
  • Process for financial organization and seeking out advisors. 10:09
  • Can you talk about the importance of portfolio diversification? 12:07
  • Importance of maintaining your overall focus on financial planning and strategies when markets are effected. 16:56
  • Could you give us one pearl for our listeners, or one key economic update that you think would be really important to the current economic situation right now? 18:49
  • Thank you Jose 23:09
  • Any final words to our listeners? 23:11
  • Outro 23:35

Jose O. Segura, is a wealth management advisor and certified business exit planner.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. For more information about Segura, visit www.joseosegura.com, reach him by email at jose_segura@wagllc.com, or call 518-867-3210 x104.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Segura reports he is a registered Representative and Financial Advisor of Park Avenue Securities LLC (PAS), 355 Lexington Avenue, 9 Fl., New York, NY 10017, 212-541-8800.

View Details

In this episode, Ashlie Leal, director of ophthalmology at FundamentalVR, discusses their fully immersive surgical training products, how virtual reality plays a role in training surgeons and more.

  • Intro :38
  • Welcome to another episode of Eye Care insider :52
  • About Ashlie Leal 1:00
  • Give me a little bit of your background – how you got into this industry and your role at FundamentalVR? 1:33
  • Can you give our listeners some background about FundamentalVR as a company, and why should eye care professionals start paying attention to your company? 2:56
  • Do you target training programs? … Is there a certain focus to your company in regards to demographics? 4:12
  • Is there any way you can describe [your virtual reality products] or any current product offers that you have that apply to eye care professionals? 7:30
  • You’re using a headset and the two arms. Is that all you would need, or would you need some sort of base mannequin head with an eyeball simulation? 9:25
  • You can do it anywhere, theoretically? And you can simulate different MIGS equipment and different ocular lens implants based on the tech simulating that equipment? 10:59
  • So, the simulation is able to carry out these multiple, intricate steps? 12:03
  • Is there current gene therapy that is utilizing your technology? Do you have a relationship with them in the sense that you provide the surgeons with the virtual reality simulations? 12:49
  • Do you have any sort of data or any procedure done with virtual reality improving complication rate and efficiency? 14:02
  • What does the future look like for virtual reality? What would you say is the major challenge, or what does your company hope to accomplish in the next few years or the decade? 15:30
  • What’s that process look like for a company to approach you for virtual reality offering to train on a new device? How long does that process take, and what are the steps to assimilate their product into your technology? 17:14
  • If someone wants to learn more, how can they contact you or your company for more information? 19:13
  • Congratulations Ashlie and FundamentalVR 19:39
  • Any final words to our listeners? 20:02
  • Outro 20:39

Ashlie Leal is director of ophthalmology, FundamentalVR.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Leal can be reached on LinkedIn or at www.fundamentalsurgery.com.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Leal reports she is director of ophthalmology at FundamentalVR.

View Details

In this episode, Allisa Song, a medical student and the CEO and co-founder of Nanodropper, discusses the inception of the device, how it can benefit the eye care industry and more.

  • Intro :38
  • Welcome to another episode of Eye Care insider :52
  • About Allisa Song 1:01
  • I want to hear your story about the history about the Nanodropper – how you came to this idea; what problem you were trying to solve; and how you got here? 2:02
  • What are the major advantages of your product? Why doesn’t our standard bottle function properly like that? 5:06
  • Can this go on every eyedrop bottle? 6:49
  • Is there any sort of data that we can look at that shows how much volume of the prescription is saved? 7:51
  • Can you talk to me about how industry has taken this? What is your take on how they feel about your product? 12:15
  • How are you distributing your product to the consumers and to the masses? What are your channels to get the product out there? 15:36
  • What do you think the future holds for Nanodropper? Where do you see this going in the next 3 to 5 years? 17:04
  • Is there any information that you can provide to our listeners can go to and learn more about your story? 18:23
  • Congratulations again Allisa 19:03
  • You’ll be graduating from medical school pretty soon? 19:15
  • Any final words to our listeners? 19:50
  • Outro 20:26

Allisa Song, is a Mayo Clinic Alix School of Medicine medical student and the CEO and co-founder of Nanodropper. Song is a serial entrepreneur and inventor with a background in Clean Tech, neuroscience, and harm reduction. In addition to her proven track record of successful fundraising, she has led her teams to dozens of business and design awards, including her most recent USPTO Collegiate Inventor medal awarded by the National Inventors Hall of Fame.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Song can be reached at support@nanodropper.com.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Song is the CEO and co-founder of Nanodropper and serves as an advisor for Bedo Solutions.

View Details

In this episode, Arthur Benjamin, MD, discusses dry eye treatment and trends, the challenges dry eye patients and the eye care professionals treating them and more.

  • Intro :37
  • Welcome to another episode of Eye Care insider :51
  • About Arthur Benjamin, MD 1:02
  • I wonder if you could talk about your training and what you currently do now? 1:39
  • Could you talk about what you’ve seen throughout the years and what you’ve seen in the trends in dry eye and how it has expanded in the population? 2:56
  • What is your current algorithm for someone with dry eye? How do you manage that? 5:01
  • Once you do determine they have moderate dry eye where do you start with the patient or the treatment paradigm? 7:00
  • With the OptiLight treatment option … what do you tell patients? What should they be expecting? 9:54
  • I recently saw that there’s been a campaign from OptiLight involving Mandy Moore. Could you talk about that campaign and discuss it a little bit further? 12:54
  • What do you think is the most important topic or issue or challenge that are facing dry eye patients today or eye care professionals treating patients with dry eye? 16:07
  • What a fascinating discussion 17:43
  • Any last words? 17:55
  • Outro 18:09

Arthur Benjamin, MD, is a clinical assistant professor at the Jules Stein/Doheny Eye Institute at UCLA’s Geffen School of Medicine and is in private practice at Benjamin Eye Institute.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Dr. Benjamin can be contacted by going to BenjaminEye.com.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Benjamin reports no relevant financial disclosures.

View Details

In this episode, Dhruvin Patel, MCOptom, discusses the short- and long-term effects of blue light on our eyes, how the pandemic has exacerbated these effects and how his company, Ocushield, is looking to help protect eyes from blue light.

  • Intro :01
  • Patel’s introduction and background :43
  • The science and necessity behind blue light blocking filters 5:35
  • Short-term effects of blue light on the eyes 7:15
  • Long-term effects of blue light on the eyes 8:24
  • Are eye care professionals doing enough to promote blue light protection? 12:11
  • Has the pandemic affected the demand/awareness of blue light related products? 14:25
  • Ocushield filters: what they are and how to get them 16:15
  • What makes Ocushield unique in the blue light/ophthalmic landscape? 19:03
  • How to contact Dr. Patel and Ocushield 20:31
  • Patel’s final thoughts on our visual system and the importance of protecting it 21:11
  • Outro 22:01

Dhruvin Patel, MCOptom, is an optometrist and the founder of Ocushield. You can send your comments/questions directly to him at www.ocushield.com. Follow him on Instagram, Facebook and Twitter @getocushield.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Patel is founder of Ocushield.

View Details

In this episode I share my top 5 predictions in ophthalmology for 2022, including my thoughts on the future of COVID-19 and ocular gene therapy.

  • Welcome to another exciting episode of Eye Care insider :50
  • My top 5 predictions for 2022 1:16
  • Prediction #1 – on COVID-19 1:27
  • Prediction #2 – on wet AMD 2:43
  • Prediction #3 – on ocular gene therapy 4:05
  • Prediction #4 – on geographic atrophy 5:05
  • Prediction #5 – on ophthalmology media platforms 7:23
  • Thanks for listening 9:20

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact Mogan by going to the company’s website, www.parkplacepayments.com or at Linkedin.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

View Details

In this episode, Jennifer L. Mogan, MD, discusses her path into medicine, the importance of the credit card process and how it can be beneficial for eyecare practices.

  • Welcome to another exciting episode of Eye Care insider :14
  • What led to the inception of the ‘Doctorpreneurship’ series? :29
  • About Mogan 2:16
  • The interview 2:47
  • Give us an idea of your background, your training and why you went to medicine? 3:12
  • How in the world did you get involved with credit card processing? 4:12
  • Can you summarize the whole credit card processing process? Why should eye care professional or anybody in health care be aware of this structure and how will it affect their bottom line? 5:51
  • So, what are you finding in the market? Are physicians aware of this, are they not? And if they’re not, how much is this potentially costing a practice? 11:37
  • How can they implement these strategies in practice or what services can your company offer eyecare professionals in helping to solve this problem? 12:46
  • Have you seen an uptake in business recently because of practices trying to minimize their expenses by lowering these rates? 13:57
  • How to find Mogan 14:35
  • What do you love about being a Doctorpreneur and do you have any advice or pearls for the audience? 15:02
  • Thank you, Dr. Mogan for all your great advice and tips 16:07

Jennifer L. Mogan, MD, is an anesthesiology specialist with Rochester Regional Health and a senior account specialist for Park Place Payments.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact Mogan by going to the company’s website, www.parkplacepayments.com or at Linkedin.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Mogan is a senior account specialist for Park Place Payments.

View Details

In this episode, Sue Washer, BS, MBA, discusses gene therapy in ophthalmology, ATGC’s clinical trial progress, as well as current and future challenges faced by both the cell therapy industry and ophthalmology.

  • Welcome to another exciting episode of Eye Care insider :13
  • About Washer 1:51
  • Can you discuss what is gene therapy? How does it work on a basic level? 4:53
  • How do companies like AGTC make gene therapy work for diseases that may not affect as many people but still make it financially successful for investors? 7:11
  • Could you talk about where you are in the X-Linked Retinitis Pigmentosa candidate trials? 11:08
  • Is there an estimated timeline that you have for initial data read out? 14:56
  • You have another candidate for achromatopsia … I was reading you had some new data released. Could you go into more details about that? 16:23
  • What do you think is the most important topic or challenge you see facing the gene therapy industry and ophthalmology today and in the future? 20:56
  • Thank you so much for your insight into this fascinating topic 23:22
  • How to find out more about AGTC 23:31
  • Thank you for listening 24:15

Sue Washer, BS, MBA is the president and chief executive officer of AGTC.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact AGTC through the company’s website at www.atgc.com.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Washer is the president and CEO of AGTC.

View Details

In this episode, the third of a three-part series, John B. Pinto discusses some of the future megatrends expected for ophthalmic practices, challenge practices may face in the future, and more.

  • Intro :13
  • What you think the megatrends are going to be over the next decade or so in the ophthalmic practices :50
  • What do you think is the most important topic or issue or challenge facing ophthalmic practices now and in the future? 4:46
  • If our listeners wanted to learn more, what’s the best way to contact you? 10:02
  • I really appreciate you and all your great advice 10:47
  • Any final words? 11:00
  • Thank you so much John, I appreciate it 11:16

John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto’s Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership.

UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

View Details

In this second episode of a three-part series, John B. Pinto discusses the job market for early-career professionals and new graduates, his perspective on what ophthalmologists have learned from the pandemic and the role telemedicine will play in the future of ophthalmology.

  • Intro :14
  • What is the current negotiation position in the market for early-career and new graduate ophthalmic practice physicians? :41
  • I’d love to hear your perspective on what we have learned about our practices after a year of this pandemic 3:35
  • How is the telemedicine trend going now? Is telemedicine here to stay? 11:09
  • Tell us about your upcoming book and your insight into it? 12:59
  • Stay tuned for the next episode of this special three-part miniseries 17:38

John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto’s Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership.

UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

View Details

In this episode, the first of a three-part series, John B. Pinto discusses how he got started in ophthalmic practice management, shares an historical perspective on the field, plus his advice for physicians.

  • Intro :16
  • About John Pinto :54
  • On Pinto’s background, why he went into the ophthalmic practice management industry 1:39
  • Can you give listeners a historical perspective of how has ophthalmic practice management changed or evolved over the last 40 years? 7:13
  • What is the current state of ophthalmic practice management in America today? 13:11
  • Could you give a key pearl for how to handle practice management as an early- or mid-career physician as well as a late-career/ retirement-age physician? 16:02
  • In your experience, what would you say would be the average age of full retirement in ophthalmology? 23:56
  • Stay tuned for the next episode of this special three-part miniseries 27:19

John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto’s Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership.

UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

View Details

In this episode, Rick Eiswirth, president and CEO of Alimera Sciences, shares the latest on the phase 4 New Day study of Iluvien, as well as his predictions for the future of ophthalmology.

  • Intro :13
  • In this episode :18
  • About Rick Eiswirth :23
  • What’s your background? How did you get into the ophthalmology industry? 0:51
  • What are the benefits of Iluvien (fluocinolone acetonide intravitreal implant, Alimera Sciences)? Is this an ideal treatment for 2021? 3:36
  • How do you get retina specialists more onboard with using intravitreal steroids earlier, given anti-VEGFs’ predominance? 6:26
  • Can you tell us more about the New Day trial? 8:10
  • Which trial outcome would be considered a success for Iluvien? 11:58
  • Do you anticipate a cost savings? 13:58
  • What’s the status of the New Day trial? 15:15
  • How has COVID changed the industry landscape in ophthalmology? 16:20
  • Are there any new products in the pipeline? 18:38
  • Iluvien is approved in other countries for uveitis 20:36
  • What have you seen from retina specialists; are there longer efficacy rates? 22:10
  • What do you think is the most important challenge the ophthalmic community will face in the future? 23:17
  • Thanks for listening 24:36

Rick Eiswirth is president and CEO of Alimera Sciences.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: Eiswirth is president and CEO of Alimera Sciences. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.

View Details

In this episode, Cathleen M. McCabe, MD, chief medical officer of Eye Health America, shares her insights and perspectives on intraocular lenses, MIGS, dry eye and more.

  • Intro :14
  • In this episode :21
  • About Cathleen M. McCabe, MD :28
  • What is your favorite intraocular lens implant to use and why? 2:24
  • What is your favorite minimally invasive glaucoma surgery (MIGS) to use and why? 4:03
  • What is your favorite dry-eye treatment to use and why? 4:49
  • What’s your preferred technique for secondary IOLs? 6:29
  • How has the role of women in ophthalmology changed throughout the years? 8:46
  • How did you get involved with international work? How has the pandemic affected this? 10:55
  • Tell us about your mission work. What are you currently involved in? 12:54
  • What is the most important topic/issue/challenge facing ophthalmology now or in the future? 15:11
  • Final words from Dr. McCabe 16:46

Cathleen M. McCabe, MD, is chief medical officer of Eye Health America; medical director of The Eye Associates and president of Outpatient Ophthalmic Surgery Society.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

To learn more about the Global Education & Research Society of Ophthalmology (or GERSO), visit https://www.gerso.org.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.

View Details

In this special episode, I sit down with this week’s co-host, my wife Yasmin P. Mali, MD, to discuss my top 5 predictions in ophthalmology in the new year. Stay tuned for a special announcement at the end of the show.

  • Intro :14
  • In this episode :21
  • About Yasmin P. Mali, MD :35
  • Mali’s first prediction: The human spirit and innovation will triumph over the headline-dominating COVID-19 1:16
  • Yasmin Mali’s thoughts on the first predictions 2:58
  • Mali’s second prediction: The competition battle lines will be drawn for ocular therapeutics in the most common eye disease markets 4:04
  • Thoughts on the potential products in 2021 6:25
  • Mali’s third prediction: Increased use of artificial intelligence in clinical ophthalmology 8:18
  • Any advances in artificial intelligence for pediatric ophthalmology? 10:15
  • Mali’s fourth prediction: Telemedicine platforms will still play a role in ophthalmology 11:24
  • Thoughts on telemedicine in the pediatric ophthalmology community 13:44
  • Mali’s fifth prediction: Virtual ophthalmology conference options will remain present for the majority of 2021 15:17
  • Mali’s thoughts on the virtual meetings attended in 2020 17:10
  • Mali’s bonus announcement 18:34
  • Yasmin Mali’s final words 18:48

Yasmin P. Mali, MD, is a board-certified ophthalmologist and fellowship trained pediatric ophthalmologist. Mali is currently faculty at Lake Erie College of Osteopathic Medicine in Bradenton, Florida.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Yasmin Mali, MD, reports no relevant financial disclosures.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

View Details

In this episode, I sit down with wealth management advisor Jose Segura to discuss financial planning for medical professionals. Segura will also discuss some of the better investment strategies for eye care professionals.

  • Intro :14
  • In this episode :21
  • About Segura :30
  • The interview 1:30
  • Who is Jose Segura? 1:45
  • Why the focus on medical professionals and physicians? 3:45
  • Where should an eye care professional start regarding financial planning? 6:15
  • As a financial professional, what strategies do you use to help them start getting organized? 8:45
  • What’s the best investment? What do you tell an eye care professional about the different strategies about investing? 11:35
  • Is it best to have a team of investors or to have a professional to help navigate changing environments? 15:18
  • How do you, from a financial standpoint, help to weather those economic headwinds? What’s the best strategy for eye care professionals? 16:40
  • What do you think is the most important financial pearl in regards to financial planning and their financial future? 20:35
  • Segura’s final words 21:55

Jose Segura is a wealth management advisor and business exit planner for Wealth Advisory Group, LLC and a financial advisor with Park Avenue Securities, LLC.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. For more information about Segura, visit www.joseosegura.com, reach him by email at jose_segura@wagllc.com, or call 518-221-4832.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

View Details

In this episode, I sit down with Kester Nahen, PhD, as we discuss the use of artificial intelligence and telemedicine among retina specialists. Nahen will also discuss Notal Vision’s ForseeHome device for monitoring and the company’s Home OCT artificial intelligence-enable platform for monitoring AMD.

  • Intro :14
  • In this episode :21
  • About Dr. Nahen 1:24
  • The interview 1:42
  • The background of Kester Nahen 2:00
  • Nahen’s thoughts on the current state of telemedicine and artificial intelligence 5:10
  • Will artificial intelligence replace the clinical aspect of what we do? 7:42
  • About Notal Vision’s ForseeHome Device 9:30
  • The AMD criteria required for use of ForseeHome 11:54
  • As a result of COVID-19, has there been an increased interest in using ForseeHome? 13:15
  • What is the best way for ophthalmologists and eyecare providers to get more information about the ForseeHome program? 14:40
  • More details on Notal Vision’s Home OCT and will it really change and revolutionize the way retina specialists monitor patients? 16:00
  • What’s the status of the FDA approval process for the Home OCT? 21:10
  • What does Nahen think is the most important topic facing the ophthalmology industry today and what will be in the future? 23:05
  • Nahen’s final thoughts 25:30

Kester Nahen, PhD, is the chief executive officer at Notal Vision.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Nahen is the CEO of Notal Vision.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

View Details

In part 1 of this two-part series, I sit down with George B. Bartley, MD, who details the history of the American Board of Ophthalmology, plus everything you ever wanted to know about board certification and maintaining your certificate.

  • Intro :14
  • In this episode :24
  • About Dr. Bartley :49
  • The interview 1:06
  • Who is Dr. Bartley? 1:09
  • History of the ABO and Dr. Bartley’s journey with them 3:51
  • What are the benefits of having board certification? 7:50
  • What are the initial steps to becoming board certified? 11:46
  • What happens next with the postponement? 17:21
  • Once you’re board certified, how does maintenance of certification (MOC) work? 23:25
  • How does one pass the quarterly questions? 33:03
  • How many years do people need to pass to maintain certification? 35:08
  • CME vs. self-assessment CME 36:20
  • Are there any potential changes to the certification process? 37:53
  • What’s the most important issue facing the ABO, now or in the future? 41:05
  • Thank you for your service to the ABO, Dr. Bartley 42:20

George B. Bartley, MD, is chief executive officer, American Board of Ophthalmology; chief executive officer, Mayo Clinic in Florida; and The Louis and Evelyn Krueger Professor of Ophthalmology, Mayo Clinic.

Disclosures: Bartley reports the American Board of Ophthalmology reimburses Mayo Clinic for a portion of his salary and benefits. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Information about certification and maintaining certification can be found on the American Board of Ophthalmology’s website: https://abop.org. For news, updates, and announcements, visit the board’s blog at https://diplomatedigest.com. To receive personalized assistance maintaining ABO certification, contact Amy Savastano, diplomate success specialist, at 610-664-1175 or amy@abop.org.

View Details

In this interview with Joseph Nezgoda, MD, MBA, we discuss young ophthalmologists – or YOs – and the most important challenges this group faces. Nezgoda also provides his insight and advice for YOs embarking on their career.

  • Intro :13
  • In this episode :15
  • About Dr. Nezgoda :23
  • The interview :54
  • Who is Dr. Nezgoda? 1:29
  • “Ah-ha” moments 4:13
  • What is a young ophthalmologist, or YO? 8:07
  • What is the most important topic or challenge currently facing YOs? 9:57
  • What’s the ideal path – academic, private practice, or a hybrid? 11:41
  • How did you get involved in advocacy? 16:24
  • What do you think will be the biggest challenge for YOs in the future? 22:42
  • Any last advice for YOs starting their career? 26:53
  • Thanks for listening! 29:35

Joseph Nezgoda, MD, MBA, is an ophthalmologist and retina specialist in private practice at Retina Macula Institute in West Palm Beach, Fla. He is also vice president of education at Florida Society of Ophthalmology; editor of ONE Network Retina, American Academy of Ophthalmology; and delegate to the AMA, American Society of Retina Specialists.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Nezgoda reports no relevant financial disclosures.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Dr. Nezgoda can be reached via www.retinamacula.org

View Details

In this episode, John S. Pollack, MD, discusses how he got started with the American Society of Retina Specialists, gives the scoop on the PAT survey and provides career advice for young retina specialists.

  • Intro :15
  • In this episode :18
  • About Dr. Pollack :24
  • The interview :45
  • Who is Dr. Pollack? 1:10
  • What’s your favorite part about the field of retina? 2:37
  • How did you get involved with the ASRS? 3:58
  • Who write the questions for the PAT survey? 5:54
  • How should community retina specialists utilize and view the PAT survey? 7:04
  • Are you currently taking responses? 7:50
  • What are the top issues ASRS will be dealing with this year? 8:12
  • Indications for surgery for epiretinal membranes: visual acuity or visual function? 8:50
  • What will have the biggest impact on retina for years to come? 15:28
  • Career advice for young retina specialists; academic vs. private practice? 18:49
  • Do you factor health care policy/reform into this decision? In 5 years, will health care be the same? 21:32
  • The Winning Pitch Challenge 22:51
  • How an idea in clinic turned into a product 26:45
  • Thanks for listening! 28:00

John S. Pollack, MD, is past president of the American Society of Retina Specialists; partner at Illinois Retina Associates, Rush University Medical Center in Chicago.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Pollack reports grant/research support from Aldeyra; consulting for Allergan, Dutch Ophthalmic Research Company, Graybug, Regeneron, REGENXBIO and Santen; founder and stock at Covalent Medical; grant support and consulting from Genentech; BOD, stock and consultant for Notal Vision; and founder and stock at Vestrum Health.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN